|
1) Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007; 35: 2191-5
|
|
|
|
2) Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341: 586-92
|
|
|
|
|
|
3) 朝倉英策. DICの病態定義, 感染症と非感染症. 日本血栓止血学会誌. 2006; 17: 284-93
|
|
|
|
|
4) Khorana AA, Kuderer NM, Francis CW, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902-7
|
|
|
|
|
|
5) Zangari M, Saghafifar F, Tricot G, et al. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003; 29: 275-82
|
|
|
|
|
|
6) Auwerda JJ, Sonneveld P, Leebeek FW, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica. 2007; 92: 279-80
|
|
|
|
|
|
7) Srkalovic G, Cameron MG, Hussein MA, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004; 101: 558-66
|
|
|
|
|
|
8) Facon T, Mary JY, Avet-Loiseau H, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007; 370: 1209-18
|
|
|
|
|
|
9) Palumbo A, Rajkumar SV, Hussein MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22: 414-23
|
|
|
|
|
|
10) Gieseler F. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost. 2008; 99: 1001-7
|
|
|
|
|
|
11) Jimenez-Zepeda VH, Dominguez-Martinez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J. 2006; 4: 11
|
|
|
|
|
|
12) Elice F, Fink L, Zangari M, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006; 134: 399-405
|
|
|
|
|
|
13) Corso A, Lorenzi A, Lazzarino M, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004; 83: 588-91
|
|
|
|
|
|
14) Kaushal V, Kaushal GP, Mehta P, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004; 2: 327-34
|
|
|
|
|
|
15) Minnema MC, Fijnheer R, Lokhorst HM, et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003; 1: 445-9
|
|
|
|
|
|
16) Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007; 138: 430-45
|
|
|
|
|
|
17) Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost. 2007; 33: 355-64
|
|
|
|
|
|
18) Caruso V, Iacoviello L, Donati MB, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006; 108: 2216-22
|
|
|
|
|
|
19) Menell JS, Cesarman GM, Hajjar KA, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999; 340: 994-1004
|
|
|
|
|
|
20) Hashimoto S, Koike T, Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia. 1994; 8: 1113-5
|
|
|
|
|
|
21) Tsukada N, Wada K, Shibata A, et al. Induction therapy with all-trans retinoic acid for acute promyelocytic leukemia: a clinical study of 10 cases, including a fatal case with thromboembolism. Intern Med. 1996; 35: 10-4
|
|
|
|
|
22) Brown JE, Olujohungbe A, Scarffe JH, et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol. 2000; 110: 1010-2
|
|
|
|
|
|
23) Levin MD, Betjes MG, Leebeek FW, et al. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica. 2003; 88: ECR21
|
|
|
|
|
|
24) Charytan C, Purtilo D. Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy. N Engl J Med. 1969; 280: 1102-4
|
|
|
|
|
|
25) Ratnoff OD. Epsilon aminocaproic acid−a dangerous weapon. N Engl J Med. 1969; 280: 1124-5
|
|
|
|
|
|
26) Ontachi Y, Asakura H, Nakao S, et al. Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica. 2005; 90 Suppl: ECR29
|
|
|
|
|
|
27) Koseki M, Asada N, Matsue K, et al. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol. 2007; 86: 403-6
|
|
|
|
|